A prospective, 1-year follow-up study of postural tachycardia syndrome

Mayo Clin Proc. 2012 Aug;87(8):746-52. doi: 10.1016/j.mayocp.2012.02.020. Epub 2012 Jul 15.

Abstract

Objective: To prospectively evaluate patients who met standard criteria for postural tachycardia syndrome (POTS), at baseline and 1-year follow-up, using standard clinical and laboratory methods to assess autonomic function.

Methods: Fifty-eight patients met the study criteria (orthostatic symptoms and a heart rate increment of ≥ 30 beats/min on head-up tilt) and completed 12 months of follow-up. All patients were enrolled and completed the study from January 16, 2006, through April 15, 2009. Patients underwent standardized autonomic testing, including head-up tilt, clinical assessment, and validated questionnaires designed to determine the severity of autonomic symptoms.

Results: Patients were predominantly young females (n=49, 84%), with 20 patients (34%) reporting an antecedent viral infection before onset of symptoms. More than one-third (37%) no longer fulfilled tilt criteria for POTS on follow-up, although heart rate increment on head-up tilt did not differ significantly at 1 year (33.8 ± 15.1 beats/min) compared with baseline (37.8 ± 14.6 beats/min) for the entire cohort. Orthostatic symptoms improved in most patients. Autonomic dysfunction was mild as defined by a Composite Autonomic Severity Score of 3 or less in 55 patients (95%) at baseline and 48 patients (92%) at 1 year.

Conclusion: To our knowledge, this is the first prospective study of the clinical outcomes of patients with POTS. Orthostatic symptoms improved in our patients, with more than one-third of patients no longer fulfilling tilt criteria for POTS, although the overall group change in heart rate increment was modest. Our data are in keeping with a relatively favorable prognosis in most patients with POTS.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-1 Receptor Agonists / therapeutic use
  • Adrenergic beta-1 Receptor Antagonists / therapeutic use
  • Adult
  • Anti-Inflammatory Agents / therapeutic use
  • Atenolol / therapeutic use
  • Cholinesterase Inhibitors / therapeutic use
  • Female
  • Fludrocortisone / therapeutic use
  • Follow-Up Studies
  • Heart Rate
  • Humans
  • Male
  • Metoprolol / therapeutic use
  • Midodrine / therapeutic use
  • Nadolol / therapeutic use
  • Norepinephrine / blood
  • Postural Orthostatic Tachycardia Syndrome / drug therapy
  • Postural Orthostatic Tachycardia Syndrome / epidemiology*
  • Propranolol / therapeutic use
  • Prospective Studies
  • Pyridostigmine Bromide / therapeutic use
  • Severity of Illness Index
  • Sodium / urine
  • Tilt-Table Test
  • Virus Diseases / epidemiology

Substances

  • Adrenergic alpha-1 Receptor Agonists
  • Adrenergic beta-1 Receptor Antagonists
  • Anti-Inflammatory Agents
  • Cholinesterase Inhibitors
  • Nadolol
  • Atenolol
  • Midodrine
  • Sodium
  • Propranolol
  • Metoprolol
  • Pyridostigmine Bromide
  • Fludrocortisone
  • Norepinephrine